Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan firm strikes Japanese prostaglandin deal

This article was originally published in Scrip

Executive Summary

Taiwan Liposome Company (TLC) has linked up with the Japanese generics firm Nihon Generic for the development and marketing in Japan of a stable liposome formulation of the peripheral vasodilator prostaglandin E1 (alprostadil). The main branded version of lipo-alprostadil in Japan is co-marketed by Taisho and Mitsubishi Tanabe Pharma as Palux/Liple and is forecast to have total sales of close to ¥20 billion ($185.5 million) this fiscal year. Several other companies also market alternative lipo-alprostadil preparations. TLC has developed proprietary liposome-based encapsulation technology which it says inhibits the degradation of alprostadil, and is also developing formulations in the oncology field.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel